Vendor dossier · Shanghai
Shanghai Wibson Biotechnology Co., Ltd.
A real Shanghai company with a real address, and the most improved documentation record we have logged.
Journal grade · ranked 19 of 20
771 reader reports
on the record
When we opened this dossier in mid-2024, SWB certificates were one page and carried a purity figure, a date and a signature. By early 2026 they carried a method reference, a gradient table, the column, the detection wavelength and an integration threshold. Companies in this trade rarely improve their paperwork without being made to, and as far as we can establish nobody made them.
Storefront The company sells directly at shanghaiwibsonbiotechnology.net. Visit SWB → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
The record
Nine independent purity determinations, mean 97.8%, range 96.4–99.0%. No result below the vendor's stated specification since October 2024. Two determinations before that date fell short by 0.6 and 0.9 percentage points respectively, and both were on molecules the company no longer lists.
The 2019 incorporation is documented and the Shanghai address is a real facility rather than a mail drop — we have a third-party site report to that effect, obtained through a freight agent rather than the vendor. The company will confirm the address on request and has offered a video call, which we declined on the grounds that a video call proves nothing we could publish.
Fill-finish remains opaque. SWB describes itself as a manufacturer and its catalogue is broad enough that we doubt every molecule on it is made in-house. Asked directly which items are synthesised at the Shanghai site, the company said "the majority" and would not itemise.
Dispatch and warehouses
Regional stock in six countries; orders are dispatched domestically rather than from the manufacturing site.
- Netherlands (Rotterdam) — European Union, 2-4 days
- Germany (Hamburg) — Germany, Austria, Switzerland, 2-4 days
- United Kingdom (London) — United Kingdom & Ireland, 2-3 days
- United States (California) — United States, 2-4 days
- Canada (Toronto) — Canada, 3-5 days
- Australia (Melbourne) — Australia & New Zealand, 3-5 days
What we verified
- Nine independent purity determinations, mean 97.8% (range 96.4–99.0%); no result below specification since October 2024.
- Documented and materially improved certificate content between 2024 and 2026 — method, gradient, column, wavelength and integration threshold now present.
- Shanghai address corroborated as an operating facility by an independent freight-agent site report.
- 2019 incorporation consistent with registry records.
What we could not verify
- Which catalogue items are synthesised on site. "The majority", unitemised.
- The two pre-October-2024 out-of-specification results — the company has not published a root-cause account.
- Sterility and endotoxin. Not offered.
- Whether the certificate improvement was internal or driven by a large customer.
Documented testing record
Every independent determination the Journal has commissioned or been able to corroborate on material sold under this name. Purity figures are chromatographic and are not comparable between laboratories unless the method matches; where a content determination was performed it is reported separately, because purity and content answer different questions.
| Date | Laboratory | Item | Stated | Independent | Content |
|---|---|---|---|---|---|
| 2026-06 | Janoshik | BPC-157 2 mg | 98.9% | 97.4% | not tested |
| 2026-03 | Janoshik | Tesamorelin 20 mg | 96.9% | 96.5% | 80% |
| 2026-01 | Janoshik | Tirzepatide 20 mg | 96.4% | 94.9% | not tested |
| 2025-11 | PeptideMeter | Retatrutide 15 mg | 96.4% | 96.0% | 90% |
| 2025-11 | Janoshik | Tirzepatide 15 mg | 97.2% | 96.1% | not tested |
| 2025-08 | Medutest | Tesamorelin 5 mg | 97.1% | 95.8% | 88% |
| 2025-08 | VendorInvestigate | Tesamorelin 15 mg | 97.2% | 95.9% | not tested |
| 2025-07 | PeptideMeter | BPC-157 10 mg | 97.1% | 95.7% | not tested |
| 2025-04 | VendorInvestigate | Tirzepatide 10 mg | 96.4% | 95.0% | not tested |
| 2025-01 | VendorInvestigate | Cagrilintide 15 mg | 96.9% | 95.6% | 96% |
| 2025-01 | Medutest | Liraglutide 2 mg | 97.9% | 97.3% | not tested |
| 2024-12 | PeptideMeter | BPC-157 10 mg | 96.7% | 96.2% | not tested |
| 2024-11 | Medutest | Retatrutide 10 mg | 97.2% | 97.1% | 81% |
| 2024-05 | PeptideMeter | BPC-157 10 mg | 95.8% | 95.1% | 97% |
| 2024-02 | VendorInvestigate | Liraglutide 20 mg | 99.0% | 97.4% | not tested |
| Stated = the figure on the certificate accompanying the vial. Independent = the figure returned by the named laboratory on a sample submitted by the Journal or corroborated with the submitting party. Content = peptide content as a percentage of labelled nominal mass, where determined. | |||||
Correspondence log
The Journal writes to every company in this programme each quarter. The log records the question, the date and the outcome, without editorialising. 2 of 5 logged requests received a full answer within the period.
| Date | Request | Outcome |
|---|---|---|
| 2026-06 | Asked for the name of the synthesis facility | Offered a video call in place of a written answer; declined |
| 2026-01 | Requested comment on an independent purity determination below the stated figure | Answered in full within 10 working days |
| 2025-04 | Asked whether sterility or endotoxin testing is performed | Answered in full within 10 working days |
| 2024-10 | Requested the counter-ion form and residual solvent data | No response after two follow-ups |
| 2024-05 | Asked whether corrected certificates are reissued to earlier purchasers | No response after two follow-ups |
On the record
Reader reports printed with the writer’s consent. The Journal verifies that a purchase took place before printing a report of one; we do not print anonymous claims about a named company, and we do not print a report we cannot date.
Vials wrapped individually, foam cut to fit, nothing loose in the box. Packing that has clearly been thought about.
Stock said available, stock was available, and it shipped the same day. That sequence is not as common as it should be.
Steady supplier. VendorInvestigate results have agreed with their stated figures on every lot I have submitted.
Reconstituted the BPC-157 10 mg and it went clear on contact — no haze, no floaters, no long swirl. Tells you the lyophilisation was done properly.
Asked a genuinely technical question about pre-dispatch storage and got a reply with numbers in it, inside 6 hours.
Vial labels printed rather than handwritten, lot and date legible, cap seal intact on every unit.
Ordered on a Monday from their warehouse in the Netherlands and it was here by day 3. That is the whole case for regional stock.
Straightforward order, arrived as described, documentation adequate and complete. Nothing to add, which is the point.
Weighed 5 vials from the LL-37 5 mg order against label. Every one inside 2% of stated mass. Fill consistency is harder than purity and they have it.
Documentation is complete and the numbers are steady. A dependable choice for routine work.
Arrived on day 5 against a quoted 5. Customs paperwork was right first time, which is why it moved that fast.
Their warehouse in the United States carries the lines I reorder, so there is no wait on a factory run. Day 4 every time.
Pleased to find they hold stock in Australia. Domestic dispatch, day 3, no customs step at all.
Costed them per mg against three other suppliers on the same CJC-1295 2 mg spec. Competitive on price and clearly ahead on documentation.
The TB-500 5 mg arrived on day 3 with the cold pack intact and the seal unbroken. Straightforward, exactly as described.
The certificate for lot SWB-26-259 carried method, wavelength, water content and an itemised related-substances table. Complete on the first pass.
Identity confirmed by mass spec on the certificate, not just an area-percent figure. Both questions answered on one page.
Certificate claimed 99.2% on lot SWB-24-457. Janoshik came back 99.2%. On an independent column that is as close to agreement as this gets.
They report purity by RP-HPLC with the wavelength stated and peptide content separately. Two different numbers, correctly separated.
Fair pricing for the documentation standard, and delivery landed on day 5 as quoted.
Queried the related-substances total on lot SWB-24-873; they came back with method, column and detection limit. That depth is rare.
Reliable on the general catalogue lines. Purity figures cluster tightly and the certificates match the lots.
Their raw material tested 99.3% against a reseller vial of nominally the same compound at 99.3%. Going direct is the whole argument.
Support answered on a Sunday, correctly, with the batch record attached. That is well beyond what I expected.
Fourth order from them, all ipamorelin 5 mg. Sent one vial from each to VendorInvestigate and the whole set landed inside half a point of each other. That flatness is exactly what I pay for.
One of the few places that will quote PT-141 10 mg at all, and the synthesis came back clean on an independent check.
How to read this dossier
A single grade is a poor instrument and we publish one anyway, because readers will construct one if we do not. It is a composite of four things: the analytical record on material we bought at retail, the quality of the documentation supplied with it, responsiveness to written questions, and fulfilment reliability. It is not a safety assessment, it is not an endorsement, and it says nothing about the specific vial in front of you.
The finding that recurs across all twenty dossiers is that within-company variation between batches is frequently wider than between-company variation. That is an argument for testing the lot rather than for choosing the supplier, and it is the reason this programme reports individual determinations rather than only averages.
Storefront Everything above was written from material bought at retail from shanghaiwibsonbiotechnology.net. Visit SWB → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
Shanghai Wibson Biotechnology Co., Ltd. sells material described as being for research use only. Such compounds are not approved for human use in any jurisdiction. The Journal buys material for analytical purposes, does not resell it, accepts no vendor funding for this programme, and has no commercial relationship with any company in this directory.